The objective of a new study published in the Yonsei Medical Journal was to explore patient and physician perspectives on allergen-specific immunotherapy (AIT) through a questionnaire survey.In this study, allergic patients who received subcutaneous immunotherapy for at least one year participated in a questionnaire developed by an expert panel of allergen and immunotherapy workgroup in Korea.Overall, 267 patients—adults 60.3%; with allergic rhinitis 91.4%; asthma 42.7%; or atopic dermatitis 20.2% from referred hospitals completed the survey. Among patients and physicians, rates of satisfaction with AIT for allergic rhinitis were 86.4% and 83.3%, respectively, and those for asthma were 85.3% and 72.9%, respectively. It was observed that pediatric asthmatic patients reported a significantly higher satisfaction rate than adult asthmatic patients after AIT. Symptom severity and drug use for allergic rhinitis and asthma decreased after AIT. Meanwhile,there was no significant difference in satisfaction rates between children and adults in allergic rhinitis. Moreover, 35.7% and 35% of allergic rhinitis and asthma patients, reported experiencing improvement in their symptoms within six months of starting AIT.Based on the perspectives of patients and physicians on AIT, it was concluded that a majority of patients were satisfied with the efficacy and safety of AIT, but not its cost. It was stated that AIT should be recommended for AR and allergic patients.